Product Description
Extended Half-Life targeting DR3. (Sourced from: https://www.shattucklabs.com/pipeline/)
Mechanisms of Action: DR3 Inhibitor
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Shattuck Labs
Company Location: AUSTIN TX 78703
Company CEO: Taylor Schreiber
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 0: Inflammatory Bowel Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|